Off-label Use of Immediate-Release Clonidine: Inequity in the Treatment of Aggression in Uruguay

Aggressive behaviours represent one of the most frequent reasons for emergency consultations at the Uruguayan National Children's Hospital. This transnosological symptomatology manifests across neurodevelopmental disorders, emotional dysregulation, complex trauma disorders, and other psychiatric conditions. In this context, the pharmacological management of acute and chronic aggressivity poses significant clinical challenges, particularly when first-line interventions unavailable, insufficient or not tolerated. 

Clonidine, a centrally acting alpha-2 adrenergic agonist, has emerged as a valuable therapeutic option for managing aggression, impulsivity, and irritability in paediatric populations with neurodevelopmental disorders (1). Randomised controlled trials have demonstrated its efficacy in reducing irritability and hyperactivity in children with autistic disorder (3) and in reducing conduct problems when added to psychostimulant medication in children with ADHD and oppositional defiant disorder (4). A systematic review concluded that clonidine may be a cost-effective pharmaceutical option for behavioural disturbances in ASD (5). 

Despite this evidence, clonidine's regulatory status in Uruguay creates a significant treatment inequity. While extended-release formulations (Kapvay, Onyda XR) are FDA-approved for ADHD in children aged 6-17 years and mentioned in diverse international guidelines, these formulations are unavailable in Uruguay. Clinicians are therefore compelled to prescribe immediate-release clonidine off-label, a practice that introduces substantial challenges. First, immediate-release clonidine requires administration three to four times daily to maintain therapeutic effect, whereas extended-release formulations allow once- or twice-daily dosing. Second, it is associated with a higher risk of sedation, hypotension, and rebound hypertension upon abrupt discontinuation. 

The Uruguayan market has a single high-cost presentation of clonidine immediate-release. Public procurement records confirm that the state purchases exclusively this formulation at a price that, combined with the need for multiple daily doses, creates an unsustainable economic burden for many families and the healthcare system. This situation perpetuates inequitable access to an effective treatment and has led health care providers to question the cost-effectiveness of continuing to stock this medication, placing its continued availability at risk. 

The unavailability of extended-release formulations in Uruguay constitutes a regulatory and market failure that disproportionately affects vulnerable populations with neurodevelopmental disorders. This inequity contravenes the principle of universal health coverage, which is a cornerstone of the Uruguayan national health system. Furthermore, it conflicts with the World Health Organization's mhGAP programme, which emphasises reducing the treatment gap and integrating evidence-based mental health interventions into primary care settings (2). Yet, Uruguayan clinicians lack access to the most appropriate clonidine formulation, forcing them to choose between a suboptimal immediate-release option or medications with more significant adverse effect profiles, such as atypical antipsychotics, which carry metabolic risks (1). 

To address this inequity, several actions are urgently required. First, the Ministry of Public Health should facilitate the registration and importation of extended-release clonidine formulations (Kapvay, Onyda XR) and guanfacine extended-release (Intuniv) for appropriate indications. Second, policies to encourage market competition and reduce medication costs are essential to break the current monopolistic situation. Third, the development of national clinical guidelines through a multidisciplinary consensus is paramount. Such guidelines would establish clear protocols for dosing, monitoring (blood pressure, heart rate, sedation), discontinuation, and criteria for specialist referral, providing clinicians with a framework for safe off-label use while awaiting the availability of extended-release formulations. Finally, local research and pharmacoeconomic studies should be conducted to evaluate the real-world effectiveness of clonidine in the Uruguayan population and to demonstrate the cost savings that appropriate pharmacological management could generate by reducing emergency consultations, hospitalisations, and disruptions to school or social placement. These studies would provide locally relevant evidence to inform clinical practice and health policy decisions. 

The off-label use of immediate-release clonidine in Uruguay is a pragmatic necessity imposed by regulatory and market barriers. The evidence supports its efficacy for aggression in neurodevelopmental disorders, but the absence of extended-release formulations creates a two-tier system: patients in countries with access to these medications receive a safer, more convenient, and more effective treatment, while Uruguayan patients must navigate the challenges of multiple daily dosing and increased adverse event risks. Addressing this inequity requires urgent regulatory action, the development of evidence-based national guidelines, and investment in local research to ensure that all patients who could benefit from this therapy have access to safe, effective, and affordable treatment. 

References:

1. Bowers RT, Weston CG, Mast RC, Nelson SC, Jackson JC. Green's child and adolescent clinical psychopharmacology. 6th ed. Philadelphia: Wolters Kluwer; 2019.
2. World Health Organization. mhGAP guideline update. Schizophr Bull. 2024;50(6):1310-25.
3. Jaselskis CA, Cook EH, Fletcher KE, Leventhal BL. Clonidine treatment of hyperactive and impulsive children with autistic disorder. J Clin Psychopharmacol. 1992;12(5):322-7.
4. Hazell PL, Stuart JE. A randomized controlled trial of clonidine added to psychostimulant medication for hyperactive and aggressive children. J Am Acad Child Adolesc Psychiatry. 2003;42(8):886-94.
5. Banas K, Sawchuk B. Clonidine as a treatment of behavioural disturbances in autism spectrum disorder: A systematic literature review. J Can Acad Child Adolesc Psychiatry. 2020;29(2):110-20.

Conflict of interest: None declared.

AI declaration: AI was used for translation and language/style editing only. The authors take  full responsibility for the content and ideas presented in the article.

This article represents the view of its author and does not necessarily represent the view of the IACAPAP's Bureau or Executive Committee.

IACAPAP Bulletin, Issue 83